MEDIFAST INC

As of September 30, 2026, MEDIFAST INC carries a market capitalization of 128.83M, placing it among publicly traded companies globally. Its enterprise value stands at -23.02M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

MEDIFAST INC's next confirmed earnings release is scheduled for February 23, 2027.

As of September 30, 2026, MEDIFAST INC has 11.18M shares outstanding.

These figures are as of September 30, 2026. The price-to-sales ratio is 0.43, and the price-to-book ratio stands at 0.71.

As of September 30, 2026, MEDIFAST INC maintains a current ratio of 4.82, meaning it holds 4.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended September 30, 2026, MEDIFAST INC posted a negative return on equity (ROE) of -20.69, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -16.08, reflecting losses generated across the asset base. The company generates approximately 788,347.37 in revenue per employee across its workforce of 380.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.15 indicates how many times MEDIFAST INC sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended September 30, 2026, MEDIFAST INC recorded 11.70M in income tax expense. The company reported a pretax loss of -29.15M and -40.85M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 30, 2026, MEDIFAST INC's stock has gained approximately 0.08% over the past 52 weeks. The 50-day moving average sits at 11.99, while the 200-day moving average is 11.32.

Over the twelve months ended September 30, 2026, MEDIFAST INC generated 299.57M in revenue and converted that into -40.85M in net income, yielding earnings per share of -3.69. EBITDA reached -22.03M, while operating income came in at -34.78M.

As of September 30, 2026, MEDIFAST INC holds 172.53M in cash and equivalents against 20.69M in total debt, resulting in a net debt position of -58.37M. Total book value stands at 180.28M, with working capital of 160.06M providing operational flexibility.

MEDIFAST INC produced -26,000.00 in operating cash flow over the twelve months ended September 30, 2026. After subtracting -3.84M in capital expenditures, free cash flow totaled -3.87M - equivalent to -0.35 per share.

Over the twelve months ended September 30, 2026, MEDIFAST INC posted a gross margin of 69.21, reflecting its pricing power and cost economics. The operating margin of -11.61 and net profit margin of -13.64 provide insight into operational efficiency.

Over the twelve months ended September 30, 2026, MEDIFAST INC paid dividends of 0.02 per share. The dividend payout ratio of -0.42 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -3.03: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.77, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to MEDIFAST INC shareholders.

As of September 30, 2026, MEDIFAST INC has an Altman Z-Score of 3.66, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.